HC Wainwright Issues Pessimistic Forecast for BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target reduced by research analysts at HC Wainwright from $60.00 to $55.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential downside of 12.17% from the stock’s previous close.

A number of other brokerages have also weighed in on BMRN. Leerink Partners lowered shares of BioMarin Pharmaceutical from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $82.00 to $60.00 in a report on Wednesday, December 3rd. Tudor Pickering set a $88.00 price objective on BioMarin Pharmaceutical in a research note on Monday, November 3rd. Wall Street Zen cut BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Sanford C. Bernstein cut their price target on shares of BioMarin Pharmaceutical from $95.00 to $88.00 and set an “outperform” rating on the stock in a report on Monday, November 3rd. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $66.00 price target on shares of BioMarin Pharmaceutical in a research report on Tuesday, October 28th. Fifteen equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $88.10.

BioMarin Pharmaceutical Trading Down 0.5%

NASDAQ BMRN opened at $62.62 on Wednesday. BioMarin Pharmaceutical has a 12 month low of $50.76 and a 12 month high of $73.51. The company has a 50-day moving average of $58.53 and a 200-day moving average of $56.08. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.83 and a quick ratio of 3.10. The company has a market cap of $12.03 billion, a P/E ratio of 35.18, a P/E/G ratio of 0.68 and a beta of 0.26.

Institutional Trading of BioMarin Pharmaceutical

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank acquired a new stake in shares of BioMarin Pharmaceutical in the 4th quarter valued at about $447,572,000. AQR Capital Management LLC grew its position in shares of BioMarin Pharmaceutical by 90.7% in the 2nd quarter. AQR Capital Management LLC now owns 5,580,573 shares of the biotechnology company’s stock worth $306,429,000 after acquiring an additional 2,654,768 shares in the last quarter. Vestal Point Capital LP increased its holdings in shares of BioMarin Pharmaceutical by 261.4% in the 4th quarter. Vestal Point Capital LP now owns 3,000,000 shares of the biotechnology company’s stock valued at $178,290,000 after acquiring an additional 2,170,000 shares during the last quarter. Capital Research Global Investors raised its position in shares of BioMarin Pharmaceutical by 547.5% during the 3rd quarter. Capital Research Global Investors now owns 2,537,596 shares of the biotechnology company’s stock valued at $137,436,000 after acquiring an additional 2,145,717 shares in the last quarter. Finally, Viking Global Investors LP raised its position in shares of BioMarin Pharmaceutical by 13.8% during the 2nd quarter. Viking Global Investors LP now owns 12,288,611 shares of the biotechnology company’s stock valued at $675,505,000 after acquiring an additional 1,488,552 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

Trending Headlines about BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: Q4 revenue beat and product momentum — Total revenue grew ~17% YoY in Q4, with VOXZOGO showing strong double‑digit growth and helping drive the quarter’s top‑line beat. Zacks: Beats Q4 Earnings and Revenue Estimates
• Positive Sentiment: Amicus acquisition expected to diversify and accelerate revenue — BioMarin announced a definitive agreement to acquire Amicus, adding marketed assets (e.g., Galafold) and late‑stage products that management says will broaden near‑term and long‑term revenue streams. PR Newswire: Q4 Results & Amicus Acquisition
• Positive Sentiment: Analysts remain constructive overall — Several firms kept Buy/Outperform ratings after the quarter (TD Cowen reiterated Buy with a high price target, Bank of America kept a Buy while trimming its target, and Oppenheimer still has an Outperform rating despite lowering its target). Analyst commentary cushions downside from the negative items. TipRanks: TD Cowen Buy Rating TipRanks: BofA Notes
• Neutral Sentiment: Company provided 2026 guidance excluding any Amicus contribution and reiterated multi‑year growth objectives; management will discuss details on the call and at upcoming investor events. PR Newswire: Guidance
• Neutral Sentiment: Management outreach — BioMarin scheduled participation in four investor conferences in March and published its earnings call/transcript and slide deck for investors to review. These events may provide additional clarity on the Amicus deal and Roctavian decision. PR Newswire: Investor Conferences Yahoo: Earnings Call Highlights
• Negative Sentiment: Voluntary withdrawal of Roctavian — BioMarin said it will withdraw its hemophilia A gene therapy (Roctavian) from the market, a material near‑term negative that raises questions about future gene‑therapy revenues, potential liabilities and regulatory scrutiny. This was the primary driver of today’s downward pressure on the stock. Zacks: Withdraw Roctavian
• Negative Sentiment: Mixed earnings/per-share results and market reaction — While revenue beat, some EPS metrics were mixed or below certain estimates and commentary on near‑term profit profiles was cautious; that mixed picture, combined with the Roctavian move, pushed sentiment negative. MarketBeat: Q4 Earnings Snapshot

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.